NCT04258475 - The Influence of Concurrent Oral Calcium Carbonate Supplementation on Steady State Pharmacokinetics of Oral Raltegravir. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 9, 2020

Primary Completion Date

June 15, 2024

Study Completion Date

January 1, 2025

Conditions

Calcium Supplementation in HIV Patients Using Raltegravir

Interventions

DRUG

Raltegravir standard dosage of 1200 mg (two 600 mg tablets) orally once daily.

Raltegravir will be dosed in a fasted state in all periods. Participants will take Raltegravir along with other ART medication.

DRUG

Calcium carbonate antacid tablet

PK analysis of different doses of calcium carbonate antacid in patients undergoing ART treatment for HIV using Raltegravir.

Trial Locations (1)

RECRUITING

The Ottawa Hospital General Campus, Ottawa